No evidence for adverse effects, such as an increase in viral infections or viral reactivation was observed which opens up the possibility to consider application of anti-IFNα treatment to HIV-infected patients to neutralize over-expression of IFNα. This evidence concerns the gene IFNA1 and viral infectious disease.